Yuanda Pharmaceutical announced on the Hong Kong Stock Exchange that the Group's international multi-center phase III clinical trial of CBT-001, a globally innovative ophthalmic drug for the treatment of pterygium, has recently reached a major clinical end. Comparing the length of conjunctival hyperemia at month 3 and pterygium lesion length at month 12 in the placebo control group, the two doses of CBT-001 showed a highly statistically significant improvement. This clinical result marks the first time that a drug has shown a therapeutic effect on pterygium disease by statistically significantly improving congestion and lesion size. Other analyses are ongoing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.